Search filters

List of works by Mary Beth Rios

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

scientific article

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

scientific article published in October 2003

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

scientific article published on 20 February 2018

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase

scientific article

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

scientific article published in November 2003

Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy

scientific article

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

scientific article published on 16 June 2009

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

scientific article published on 23 August 2017

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

scientific article

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

scientific article

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

scientific article published on 12 September 2002

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

scientific article published in September 2003

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

scientific article published on 20 February 2003

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

scientific article

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

scientific article published on 02 August 2007

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

scientific article

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

scientific article published on 11 October 2011

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

scientific article

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

scientific article published on 24 December 2003

Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia.

scientific article

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

scientific article

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

scientific article published in May 2002

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

scientific article

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

scientific article

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

scientific article

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

scientific article

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

scientific article published on 29 August 2002

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

scientific article published on 30 November 2004

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

scientific article published in July 2004

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

scientific article published on 6 January 2012

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

scientific article published on 21 February 2012

Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia

scientific article

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

scientific article

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

scientific article published on 16 August 2011

Management of molecular-targeted therapy for chronic myelogenous leukemia

scientific article

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

scientific article published on March 2007

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

scientific article

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

scientific article

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

scientific article published in December 2003

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

scientific article published in March 2003

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

scientific article

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

scientific article published on 20 December 2017

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

scientific article published in May 2003

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

scientific article

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

scientific article published on 30 January 2006

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

scientific article

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

scientific article published in January 2003

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

scientific article published on 13 March 2003

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

scientific article (publication date: August 2003)

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

scientific article published in April 2004

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

scientific article published in June 2003

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

scientific article published in September 2003

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response

scientific article

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

scientific article published in August 2005

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

scientific article published in March 2006

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

scientific article

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications

scientific article published in July 2003

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

scientific article

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

scientific article published in May 2005

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

scientific article published on 29 July 2011

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

scientific article published in July 2005

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

scientific article

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

scientific article published on June 2003

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

scientific article

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Paulina is supported by:

About Paulina

Help